Analysts See Significant Upside for JHMM and Holdings

Analysts predict a 19.79% upside for the John Hancock Multifactor Mid Cap ETF (JHMM) with notable growth potential for its holdings, Vaxcyte Inc (PCVX), Revolution Medicines Inc (RVMD), and Summit Therapeutics Inc (SMMT).

Date: 04-03-2025

AI Rating: 7

Analyst Target Pricing Insights This report underscores a favorable sentiment toward the John Hancock Multifactor Mid Cap ETF (JHMM) as the implied analyst target price of $70.92 suggests a 19.79% upside from its recent trading price of $59.20. Such bullish ratings can significantly influence investor perceptions and stock prices.

For its underlying holdings, the report highlights considerable expected growth: Vaxcyte Inc (PCVX) has a target price of $149.89, representing a robust upside of 107.89% from its current price of $72.10. Similarly, Revolution Medicines Inc (RVMD) is expected to rise by 90.40%, reaching an average target price of $73.00 from a recent price of $38.34. Lastly, Summit Therapeutics Inc (SMMT) is anticipated to climb 75.49%, moving towards a target of $33.57 from its recent price of $19.13.

This optimism can lead to increased buying pressure, especially for JHMM and its underlying stocks, as investors may seek to capitalize on expected price increases. However, the text also raises a cautionary note about whether analysts are justified in their optimistic targets, urging further research and consideration of market conditions before making investment decisions. The potential for target price downgrades exists if the anticipated targets are not based on solid data or recent developments.

Stocks: JHMM PCVX RVMD SMMT